AU2002218133A1 - Agents for the treatment of viral infections - Google Patents
Agents for the treatment of viral infectionsInfo
- Publication number
- AU2002218133A1 AU2002218133A1 AU2002218133A AU1813302A AU2002218133A1 AU 2002218133 A1 AU2002218133 A1 AU 2002218133A1 AU 2002218133 A AU2002218133 A AU 2002218133A AU 1813302 A AU1813302 A AU 1813302A AU 2002218133 A1 AU2002218133 A1 AU 2002218133A1
- Authority
- AU
- Australia
- Prior art keywords
- proteosome
- activity
- inhibit
- release
- viral infections
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10051716.1 | 2000-10-12 | ||
DE2000151716 DE10051716A1 (de) | 2000-10-12 | 2000-10-12 | Mittel zur Hemmung der Freisetzung, Reifung und Replikation von Retroviren |
DE10149398.3 | 2001-10-03 | ||
DE2001149398 DE10149398A1 (de) | 2001-10-03 | 2001-10-03 | Mittel zur Behandlung von Hepatitis-Virusinfektionen |
PCT/DE2001/003908 WO2002030455A2 (de) | 2000-10-12 | 2001-10-11 | Mittel zur behandlung von virus-infektionen |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002218133A1 true AU2002218133A1 (en) | 2002-04-22 |
Family
ID=26007405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002218133A Abandoned AU2002218133A1 (en) | 2000-10-12 | 2001-10-11 | Agents for the treatment of viral infections |
Country Status (12)
Country | Link |
---|---|
US (2) | US20040106539A1 (pt) |
EP (4) | EP1430903A1 (pt) |
JP (2) | JP2004510826A (pt) |
AT (1) | ATE338564T1 (pt) |
AU (1) | AU2002218133A1 (pt) |
CA (1) | CA2425632A1 (pt) |
CY (1) | CY1105835T1 (pt) |
DE (1) | DE50110956D1 (pt) |
DK (1) | DK1326632T3 (pt) |
ES (1) | ES2272558T3 (pt) |
PT (1) | PT1326632E (pt) |
WO (1) | WO2002030455A2 (pt) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993023574A1 (en) * | 1992-05-14 | 1993-11-25 | Kozal Michael J | Polymerase chain reaction assays for monitoring antiviral therapy |
AU2002316199A1 (en) * | 2001-06-08 | 2002-12-23 | Children's Hospital Research Foundation | Regulation of transgene expression following aav transduction |
GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
US20050203029A1 (en) * | 2002-04-05 | 2005-09-15 | Ulrich Schubert | Agents for treating <I>flaviviridae</I>infections |
US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
AU2003249930A1 (en) * | 2002-07-03 | 2004-01-23 | Charite - Universitatsmedizin Berlin | Proteaseome inhibitors for the treatment of herpesviridae infected individuals |
AU2003255287A1 (en) * | 2002-07-25 | 2004-02-16 | Charite-Universitats Medizin Berlin | Use of a proteasome inhibitor in the treatment of fibrotic diseases |
EP1638552B1 (en) * | 2003-06-20 | 2011-03-02 | Nereus Pharmaceuticals, Inc. | Use of (3.2.0) heterocyclic compounds and analogs thereof for the treatment of cancer |
ZA200600473B (en) * | 2003-06-20 | 2007-04-25 | Univ California | Salinosporamides and methods for use thereof |
US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
JP2007513878A (ja) * | 2003-11-10 | 2007-05-31 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 宿主細胞のユビキチン化の調節を通じたレトロウイルス複製の阻害 |
US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
CN102174076A (zh) | 2004-04-15 | 2011-09-07 | 普罗特奥里克斯公司 | 用于抑制蛋白酶体酶的化合物 |
WO2006017346A1 (en) * | 2004-07-13 | 2006-02-16 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH A ND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER | Treatment of viral infections by means o proteasome inhibitors |
WO2006060676A1 (en) | 2004-12-03 | 2006-06-08 | Dana Farber Cancer Institute | Compositions and methods for treating neoplastic diseases |
CA2595749A1 (en) * | 2005-01-27 | 2006-08-03 | Research Development Foundation | Combination therapy with triterpenoid compounds and proteasome inhibitors |
US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US20060193844A1 (en) * | 2005-02-28 | 2006-08-31 | Proteolix, Inc. | Methods for enzyme inhibition |
PT1948678E (pt) | 2005-11-09 | 2013-07-16 | Onyx Therapeutics Inc | Compostos para inibição de enzimas |
WO2007092944A2 (en) * | 2006-02-08 | 2007-08-16 | Introgen Therapeutics, Inc. | Compositions and methods involving gene therapy and proteasome modulation |
DE102006026464A1 (de) | 2006-06-01 | 2007-12-06 | Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma | Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus |
US7691852B2 (en) * | 2006-06-19 | 2010-04-06 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
WO2008137780A2 (en) * | 2007-05-04 | 2008-11-13 | Nereus Pharmaceuticals, Inc. | Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases |
KR20170040374A (ko) * | 2007-10-04 | 2017-04-12 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
US8394816B2 (en) * | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
WO2009140287A1 (en) | 2008-05-12 | 2009-11-19 | Nereus Pharmaceuticals, Inc. | Salinosporamide derivatives as proteasome inhibitors |
EP2351585B1 (en) * | 2008-08-29 | 2014-03-26 | Osaka University | Anti-hepatitis c virus composition comprising a nucleic acid that is directed against pa28-gamma |
MX2011004225A (es) | 2008-10-21 | 2011-06-21 | Onyx Therapeutics Inc | Terapia de combinacion con epoxicetonas peptidicas. |
TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
DE102009027754A1 (de) | 2009-07-15 | 2011-05-05 | Schubert, Ulrich, Dr. | Verfahren zur Hemmung der Reifung von dendritischen Zellen |
EP2467144A1 (en) * | 2009-07-24 | 2012-06-27 | ViroLogik GmbH | Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis |
DE102009028015A1 (de) | 2009-07-24 | 2011-01-27 | Virologik Gmbh | Mittel zur Behandlung von Hepatitis C-Infektionen |
WO2011060179A1 (en) * | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
CA2785300A1 (en) | 2009-12-22 | 2011-07-21 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
WO2011089166A1 (en) | 2010-01-19 | 2011-07-28 | Virologik Gmbh | Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection |
MA34133B1 (fr) | 2010-03-01 | 2013-04-03 | Onyx Therapeutics Inc | Composes pour inhibiteurs de l'immunoproteasome |
US8697646B2 (en) | 2010-04-07 | 2014-04-15 | Onyx Therapeutics, Inc. | Crystalline peptide epoxyketone immunoproteasome inhibitor |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
GB2515942A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV |
US8853176B2 (en) | 2011-10-21 | 2014-10-07 | Abbvie Inc. | Methods for treating HCV |
EP2662094B1 (en) | 2012-05-08 | 2024-04-17 | Onyx Therapeutics, Inc. | Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors |
US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
US20150328240A1 (en) * | 2014-05-19 | 2015-11-19 | Carl Hilliard | Product and delivery system for application of antimicrobial treatment designed to inhibit pathegens from entering or leaving a respitory system and to remove pathogens from wounds, ears or other body cavities, and methods of use |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07170998A (ja) * | 1993-09-07 | 1995-07-11 | Yissum Res Dev Co Of Hebrew Univ Of Jerusalem | NF−κBの調節方法 |
US6913767B1 (en) * | 1993-10-25 | 2005-07-05 | Genentech, Inc. | Compositions for microencapsulation of antigens for use as vaccines |
US5872206A (en) | 1994-10-06 | 1999-02-16 | The General Hospital Corporation | Compositions and methods for interfering wtih hepatitis B virus infection |
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6335358B1 (en) * | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
BR9712544B1 (pt) * | 1996-10-18 | 2013-10-22 | Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos | |
JP2001517631A (ja) | 1997-09-25 | 2001-10-09 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したNF−κBの活性化に干渉する剤 |
CA2219867A1 (en) | 1997-10-31 | 1999-04-30 | Jiangping Wu | The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
GB9806815D0 (en) * | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
AU750369B2 (en) * | 1998-04-23 | 2002-07-18 | Cortech, Inc. | Cysteine protease inhibitors |
FR2779653B1 (fr) * | 1998-06-11 | 2002-12-20 | Inst Nat Sante Rech Med | Utilisation de composes modulateurs du proteasome en therapie |
JP4503182B2 (ja) | 1998-10-20 | 2010-07-14 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | プロテアソーム・インヒビター薬物作用のモニター方法 |
AU1930900A (en) | 1998-12-04 | 2000-06-26 | University Of Maryland Biotechnology Institute | Use of protease inhibitors to modulate cellular pathways, immunity and therapiesassociated therewith |
US6329171B1 (en) * | 1999-09-30 | 2001-12-11 | Millennium Pharmaceuticals, Inc. | 23484, A novel human ubiquitin protease |
CA2396677A1 (en) * | 1999-12-23 | 2001-06-28 | The Board Of Regents Of The University Of Texas System | Inhibition of cellular proteases |
-
2001
- 2001-10-11 DK DK01986607T patent/DK1326632T3/da active
- 2001-10-11 ES ES01986607T patent/ES2272558T3/es not_active Expired - Lifetime
- 2001-10-11 WO PCT/DE2001/003908 patent/WO2002030455A2/de active IP Right Grant
- 2001-10-11 JP JP2002533894A patent/JP2004510826A/ja active Pending
- 2001-10-11 CA CA002425632A patent/CA2425632A1/en not_active Abandoned
- 2001-10-11 PT PT01986607T patent/PT1326632E/pt unknown
- 2001-10-11 EP EP04090076A patent/EP1430903A1/de not_active Ceased
- 2001-10-11 AU AU2002218133A patent/AU2002218133A1/en not_active Abandoned
- 2001-10-11 DE DE50110956T patent/DE50110956D1/de not_active Expired - Lifetime
- 2001-10-11 US US10/398,993 patent/US20040106539A1/en not_active Abandoned
- 2001-10-11 AT AT01986607T patent/ATE338564T1/de active
- 2001-10-11 EP EP10182351A patent/EP2301565A1/de not_active Withdrawn
- 2001-10-11 EP EP10182253A patent/EP2305291A1/de not_active Ceased
- 2001-10-11 EP EP01986607A patent/EP1326632B1/de not_active Expired - Lifetime
-
2006
- 2006-12-06 CY CY20061101761T patent/CY1105835T1/el unknown
-
2007
- 2007-04-04 US US11/732,797 patent/US20070265194A1/en not_active Abandoned
-
2008
- 2008-10-07 JP JP2008260772A patent/JP2009046507A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2004510826A (ja) | 2004-04-08 |
DK1326632T3 (da) | 2007-01-15 |
PT1326632E (pt) | 2007-01-31 |
EP1326632A2 (de) | 2003-07-16 |
US20040106539A1 (en) | 2004-06-03 |
EP2305291A1 (de) | 2011-04-06 |
US20070265194A1 (en) | 2007-11-15 |
EP2301565A1 (de) | 2011-03-30 |
CA2425632A1 (en) | 2002-04-18 |
CY1105835T1 (el) | 2011-02-02 |
EP1326632B1 (de) | 2006-09-06 |
ES2272558T3 (es) | 2007-05-01 |
WO2002030455A2 (de) | 2002-04-18 |
DE50110956D1 (de) | 2006-10-19 |
WO2002030455A3 (de) | 2002-08-08 |
JP2009046507A (ja) | 2009-03-05 |
ATE338564T1 (de) | 2006-09-15 |
EP1430903A1 (de) | 2004-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002218133A1 (en) | Agents for the treatment of viral infections | |
EP1340744A3 (en) | Hiv protease inhibitors | |
DE69512220D1 (en) | Sulfonamidderivate als aspartylprotease-inhibitoren | |
DK0813542T3 (da) | Aminosyrehydroxyethylaminosulfonamid som retrovirale proteaseinhibitorer | |
EE9700200A (et) | Bis-aminohappe hüdroksüetüülamino-sulfoonamiidsed retroviirusliku proteaasi inhibiitorid | |
AU2658695A (en) | N-(3-amino-2-hydroxybutyl)sulphonamide derivatives as hiv protease inhibitors | |
DE69531944D1 (de) | Neue hiv-protease-inhibitoren | |
NZ306026A (en) | N-[2-hydroxy-3-sulphonyl-amino]-3-(hydrocarbylsulphonyl)hydrocarbyl-amide derivatives | |
BR9607625A (pt) | Inibidores de protease retroviral sulfonamida hidroxietilamino de aminoácido heterociclocarbonila | |
ES2176263T3 (es) | 5,6-dihidropironas derivadas como inhibidores de proteasa y agentes antivirus. | |
ES2132383T3 (es) | Inhibidores de proteasa hiv. | |
BR0102870A (pt) | Desfoliantes | |
MY117535A (en) | Hiv protease inhibitors | |
FI963073A0 (fi) | Makrosykliset difluorisatonijohdannaiset, jotka ovat käyttökelpoisia viruksia vastustavina aineina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |